Patent ID: 11938149
Assignee: NEUVIVO, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 11:
12. A method of treating Amyotrophic Lateral Sclerosis (ALS) in a subject in need thereof, the method comprising:
a) determining that the subject has a plasma level of C-reactive protein that is at least 1125 ng/mL; and
b) based on the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL, administering to the subject an amount of sodium chlorite that is therapeutically-effective for Amyotrophic Lateral Sclerosis (ALS),
wherein the subject is under age 65 and the subject is human;
wherein the subject exhibits a behavioral symptom of Amyotrophic Lateral Sclerosis (ALS);
wherein the subject exhibits a physical symptom of Amyotrophic Lateral Sclerosis (ALS);
wherein the sodium chlorite is administered in an amount ranging from 1 to 2 mg/kg by body weight of the subject;
wherein the administering occurs at least once per month for a period of at least a year;
wherein the administering occurs over a period ranging from about 0.5 to about 4 hours;
wherein the administering is parenteral;
wherein the administering of the sodium chlorite is by administration of a formulation,
wherein the formulation comprises:
a) the sodium chlorite;
b) phosphate buffer;
c) chloride ions in an amount of less than about 1% of chlorite ions in the formulation; and
d) chlorate ions in an amount of less than about 1.5% of chlorite ions in the formulation,
wherein the formulation has a pH of about 7 to about 11.